TFE3 Nuclear Expression As a Novel Biomarker of Ovarian Sclerosing Stromal Tumors and Associated with Its Histological Morphology

Overview

Journal J Ovarian Res

Publisher Biomed Central

Specialties Gynecology & Obstetrics
Reproductive Medicine

Date 2023 Aug 1

PMID 37528481

Authors

Li Zhao

Zhongfeng Yang

Yan Zhou

Yuping Liu

Qiuping Luo

Qingping Jiang

Hui Wang

Na Wang

Affiliations

Soon will be listed here.

Abstract

Sclerosing stromal tumors of the ovary are benign and tend to occur in youthful women with lobular structures at low frequencies. Three types of cells, including luteinized cells, short spindle myoid cells, and intermediate cells, are found in the lobules which abundant in the blood vessels. Currently, immunohistochemistry is used to detect normal follicles, sclerosing stromal tumors, granulosa cell tumors, and fibromas/thecomas. Our research results showed that transcription factor enhancer 3 (TFE3) was moderate to strong positive in the theca interna layer of normal follicles. TFE3 was expressed in seven out of eight sclerosing stromal tumors, mainly in luteinized cells. It did not express in 20 granulosa cell tumors. Of the nine fibromas/thecomas, TFE3 was weakly staining in 2 cases and negative in the remaining 7 cases. The expression of TFE3 was also weak in only one microcystic stromal tumor. 8 cases of sclerosing stromal tumors were analyzed by FISH using a TFE3 separation probe, and the results were negative. In short, as a nuclear transcription protein, TFE3 specifically expressed in sclerosing stromal tumors and could serve as a new marker for the diagnosis and differential diagnosis of sclerosing stromal tumors. Moreover, we speculate that TFE3 will promotes the formation of the vascular plexus after entry into the nucleus, which can further explain why sclerosing stromal tumors are different from other ovary sex-cord stromal tumors.

References

Argani P, Lal P, Hutchinson B, Lui M, Reuter V, Ladanyi M . Aberrant nuclear immunoreactivity for TFE3 in neoplasms with TFE3 gene fusions: a sensitive and specific immunohistochemical assay. Am J Surg Pathol. 2003; 27(6):750-61. DOI: 10.1097/00000478-200306000-00005. View

Panagopoulos I, Gorunova L, Lund-Iversen M, Bassarova A, Heim S . Fusion of the Genes and in Malignant Chondroid Syringoma. Cancer Genomics Proteomics. 2019; 16(5):345-351. PMC: 6727079. DOI: 10.21873/cgp.20139. View

Perera R, Di Malta C, Ballabio A . MiT/TFE Family of Transcription Factors, Lysosomes, and Cancer. Annu Rev Cancer Biol. 2019; 3:203-222. PMC: 6812561. DOI: 10.1146/annurev-cancerbio-030518-055835. View

Devins K, Young R, Watkins J . Sclerosing stromal tumour: a clinicopathological study of 100 cases of a distinctive benign ovarian stromal tumour typically occurring in the young. Histopathology. 2021; 80(2):360-368. DOI: 10.1111/his.14554. View

Katsube Y, Iwaoki Y, Silverberg S, Fujiwara A . Sclerosing stromal tumor of the ovary associated with endometrial adenocarcinoma: a case report. Gynecol Oncol. 1988; 29(3):392-8. DOI: 10.1016/0090-8258(88)90242-9. View

Deval B, Rafii A, Darai E, Hugol D, Buy J . Sclerosing stromal tumor of the ovary: color Doppler findings. Ultrasound Obstet Gynecol. 2003; 22(5):531-4. DOI: 10.1002/uog.223. View

Oliva E, Garcia-Miralles N, Vu Q, Young R . CD10 expression in pure stromal and sex cord-stromal tumors of the ovary: an immunohistochemical analysis of 101 cases. Int J Gynecol Pathol. 2007; 26(4):359-67. DOI: 10.1097/PGP.0b013e318064511c. View

Hirakawa T, Kawano Y, Mizoguchi C, Nasu K, Narahara H . Expression of angiogenic factors in sclerosing stromal tumours of the ovary. J Obstet Gynaecol. 2018; 38(5):682-685. DOI: 10.1080/01443615.2017.1397610. View

Schoolmeester J, Dao L, Sukov W, Wang L, Park K, Murali R . TFE3 translocation-associated perivascular epithelioid cell neoplasm (PEComa) of the gynecologic tract: morphology, immunophenotype, differential diagnosis. Am J Surg Pathol. 2014; 39(3):394-404. PMC: 4982474. DOI: 10.1097/PAS.0000000000000349. View

10.

Kaygusuz E, Cesur S, Cetiner H, Yavuz H, Koc N . Sclerosing stromal tumour in young women: clinicopathologic and immunohistochemical spectrum. J Clin Diagn Res. 2013; 7(9):1932-5. PMC: 3809640. DOI: 10.7860/JCDR/2013/6031.3373. View

11.

Joja I, Okuno K, Tsunoda M, Takeda Y, Sugita K, Mizutani Y . Sclerosing stromal tumor of the ovary: US, MR, and dynamic MR findings. J Comput Assist Tomogr. 2001; 25(2):201-6. DOI: 10.1097/00004728-200103000-00007. View

12.

Zhang X, Li H, Li L, Zhang H, Zhang T, Liu X . Sclerosing stromal tumor with marked atypia that mimics an undifferentiated sarcoma. Pathol Int. 2019; 70(1):53-55. DOI: 10.1111/pin.12876. View

13.

McCluggage W, Maxwell P . Immunohistochemical staining for calretinin is useful in the diagnosis of ovarian sex cord-stromal tumours. Histopathology. 2001; 38(5):403-8. DOI: 10.1046/j.1365-2559.2001.01147.x. View

14.

Chalvardjian A, Scully R . Sclerosing stromal tumors of the ovary. Cancer. 1973; 31(3):664-70. DOI: 10.1002/1097-0142(197303)31:3<664::aid-cncr2820310327>3.0.co;2-f. View

15.

Kawauchi S, Tsuji T, Kaku T, Kamura T, Nakano H, Tsuneyoshi M . Sclerosing stromal tumor of the ovary: a clinicopathologic, immunohistochemical, ultrastructural, and cytogenetic analysis with special reference to its vasculature. Am J Surg Pathol. 1998; 22(1):83-92. DOI: 10.1097/00000478-199801000-00011. View

16.

Park C, Kim H . Clinicopathological Characteristics of Ovarian Sclerosing Stromal Tumor with an Emphasis on TFE3 Overexpression. Anticancer Res. 2017; 37(10):5441-5447. DOI: 10.21873/anticanres.11972. View

17.

Irving J, Young R . Microcystic stromal tumor of the ovary: report of 16 cases of a hitherto uncharacterized distinctive ovarian neoplasm. Am J Surg Pathol. 2008; 33(3):367-75. DOI: 10.1097/PAS.0b013e31818479c3. View

18.

Ihara N, Togashi K, Todo G, Nakai A, Kojima N, Ishigaki T . Sclerosing stromal tumor of the ovary: MRI. J Comput Assist Tomogr. 1999; 23(4):555-7. DOI: 10.1097/00004728-199907000-00013. View

19.

Kim S, Da Cruz Paula A, Basili T, Dopeso H, Bi R, Pareja F . Identification of recurrent FHL2-GLI2 oncogenic fusion in sclerosing stromal tumors of the ovary. Nat Commun. 2020; 11(1):44. PMC: 6940380. DOI: 10.1038/s41467-019-13806-x. View

20.

Fang R, Wang X, Xia Q, Zhao M, Zhang H, Wang X . Nuclear translocation of ASPL-TFE3 fusion protein creates favorable metabolism by mediating autophagy in translocation renal cell carcinoma. Oncogene. 2021; 40(18):3303-3317. DOI: 10.1038/s41388-021-01776-8. View